Malani, Disha http://orcid.org/0000-0001-9614-3281
Yadav, Bhagwan
Kumar, Ashwini
Potdar, Swapnil http://orcid.org/0000-0002-2778-6918
Kontro, Mika
Kankainen, Matti
Javarappa, Komal K.
Porkka, Kimmo
Wolf, Maija
Aittokallio, Tero
Wennerberg, Krister
Heckman, Caroline A.
Murumägi, Astrid
Kallioniemi, Olli http://orcid.org/0000-0002-3231-0332
Funding for this research was provided by:
Finnish Cultural Foundation | Etelä-Karjalan Rahasto
Helsingin Yliopisto
Syöpäjärjestöt
Suomen Lääketieteen Säätiö
Sigrid Juséliuksen Säätiö
Academy of Finland
Tekes
Stiftelsen för Strategisk Forskning
Knut och Alice Wallenbergs Stiftelse
Article History
Received: 3 April 2020
Revised: 2 July 2020
Accepted: 7 July 2020
First Online: 17 July 2020
Compliance with ethical standards
:
: The senior authors have received collaborative research grants for other projects as listed: OK received research funding from Vinnova for collaboration between Astra-Zeneca, Takeda, Pelago, and Labcyte. OK is also a board member and a co-founder of Medisapiens and Sartar Therapeutics, and has received a royalty on patents licensed by Vysis-Abbot. KP received honoraria and research funding from Bristol-Myers Squibb, Celgene, Novartis, and Pfizer. CH received honoraria from Celgene, Novartis, and Roche, and research funding from Celgene, Novartis, Oncopeptides, Pfizer, and the IMI2 project HARMONY. KW received research funding from Novartis and Pfizer. MKo: research funding from AbbVie. The remaining authors declare that they have no conflict of interest.